Avadel Pharmaceuticals plc (AVDL)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Gregory J. Divis |
| Employees: | 70 |
| Web site: | avadel.com |
|
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN, L2, 15
636-449-1830
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Please log in first to see chart